Drug Trial Radar · NCT05841160
Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization
Last checked: Nov 19, 2026Latest source record: Jun 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Mar 15, 2023
Primary completion
May 7, 2023
Study completion May 12, 2023
Sponsor
- Lead sponsor
- Emalex Biosciences Inc.Industry
- Sponsor type
- Industry
- Collaborators
- PPD Development, LP; Clario
- First posted
- May 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
THOROUGH QT/QTc STUDY TO EVALUATE THE EFFECTS OF ECOPIPAM (EBS-101) ON CARDIAC REPOLARIZATION
Conditions
- QT/QTc
Interventions
Ecopipam HydrochlorideDrug
oral tablets
MoxifloxacinDrug
oral tablet
PlaceboDrug
oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate ecopipam's effect on the QTc interval after administration of therapeutic and supratherapeutic doses, compared to placebo as a negative control using C-QTc analysis.Time frame: Up to Day 25
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PPD Austin Phase 1 Clinical Research Unit
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.